Stay updated on SAGE-718 Effects in AD: Mild Cognitive Impairment Clinical Trial
Sign up to get notified when there's something new on the SAGE-718 Effects in AD: Mild Cognitive Impairment Clinical Trial page.

Latest updates to the SAGE-718 Effects in AD: Mild Cognitive Impairment Clinical Trial page
- Check4 days agoChange DetectedNo significant changes detected in the Study Details page; essential information remains unchanged.SummaryDifference0.4%

- Check11 days agoNo Change Detected
- Check33 days agoChange DetectedUpdated the page to v3.2.0 with a prominent notice about potential data/tansaction delays due to funding gaps and where to check operating status; previous v3.1.0 reference removed.SummaryDifference3%

- Check40 days agoChange DetectedUpdated the page revision from v3.0.2 to v3.1.0, indicating a new software release or document update. No changes to core content, pricing, or stock are evident.SummaryDifference0.1%

- Check47 days agoChange DetectedRebranding from Sage Therapeutics to Supernus Pharmaceuticals, Inc., with newer update/posting dates to reflect current information.SummaryDifference1%

- Check55 days agoChange DetectedThe page now shows Revision: v3.0.2, replacing v3.0.1, and the Back to Top element has been removed; this signals a simple release update with minor UI change.SummaryDifference0.2%

- Check62 days agoChange DetectedThe web page has been updated from version 3.0.0 to 3.0.1, indicating a revision in the content. There are no significant changes to core content, names, pricing, or availability.SummaryDifference0.2%

Stay in the know with updates to SAGE-718 Effects in AD: Mild Cognitive Impairment Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SAGE-718 Effects in AD: Mild Cognitive Impairment Clinical Trial page.